Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the 2020 Muscle Study Group (MSG) Annual Virtual Meeting; September 25, 2020. [abstract] RRNMF Neu J. 2020 Sep; 1(4):61.
Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Williams PA, Cates SC, Blitstein JL, Hersey JC, Kosa KM, Long VA, Singh A, Berman D. Evaluating the impact of six Supplemental Nutrition Assistance Program Education interventions on children's at-home diets. Health Educ Behav. 2015 Jun;42(3):329-38. doi: 10.1177/1090198114558589
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb;19(2):94-102.
Bauman KE, Ennett ST, Foshee VA, Pemberton M, Hicks K. Correlates of participation in a family-directed tobacco and alcohol prevention program for adolescents. Health Educ Behav. 2001 Aug 1;28(4):440-61.